ArticleBMC ophthalmology2025
Analysis of the etiology, clinical characteristics and treatment outcomes of choroidal neovascularization in Chinese children and adolescents.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bilateral idiopathic peripapillary choroidal neovascularization in a child with bruton disease: a case report.BMC ophthalmology · 2026Article
- Novel Quantitative OCTA Biomarkers of Choroidal Neovascularization and Associations With Disease Activity and Etiology.Translational vision science & technology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the etiology, clinical characteristics and treatment outcomes of choroidal neovascularization (CNV) in Chinese children and adolescents.
methodsA retrospective analysis was conducted on the clinical data, multimodal imaging and treatment outcomes of pediatric patients with CNV at Beijing Tongren Hospital from May 2014 to October 2024.
results72 children with CNV were included. The average age was 12.1 ± 3.5 years and 36 (50.0%) were male. The most common etiologies of pediatric CNV were idiopathic (37.50%), inflammatory chorioretinopathy (31.94%) and congenital or hereditary abnormalities (16.67%). Age distribution analysis showed that CNV most commonly occurred in adolescence (13-17 years, 48.61%) and school age (7-12 years, 45.83%). Idiopathic CNV was the main cause of CNV in children ≤ 12 years (43.24%), followed by inflammatory chorioretinopathy (21.62%) and congenital or hereditary abnormalities (18.92%), while the main cause of CNV in children > 12 years was inflammatory chorioretinopathy (42.86%). Most of the CNVs were subfoveal (56.3%) and all of the CNVs with complete fundus fluorescein angiography (FFA) images were classic type. Of the 58 eyes (72.5%) with complete optical coherence tomography (OCT) data, all of the CNVs were type 2. Analysis of 26 eyes treated with intravitreal anti-VEGF drugs showed that the best corrected visual acuity (BCVA) significantly improved from 0.75 ± 0.46 logMAR at baseline to 0.63 ± 0.46 logMAR at the last follow-up (p = 0.021), with 38.5% patients achieved ≥ 2-line BCVA improvement. These eyes with active CNV required a mean of 2.12 ± 0.80 injections during the follow-up period.
conclusionThe etiology and clinical characteristics of CNV in children differed from those in adults. Idiopathic, inflammatory, and congenital or hereditary CNV were the three most common etiologic factors in children. Most pediatric CNV were unilateral, type 2 and subfoveal. Pediatric CNV responded well to anti-VEGF medication and anti-VEGF drugs can significantly improve the visual acuity of children with CNV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.